University of Veterinary Medicine Vienna - Research portal

Diagrammed Link to Homepage University of Veterinary Medicine, Vienna

Selected Publication:

Type of publication: Journal Article
Type of document: Full Paper

Year: 2012

Authors: Wolfesberger, B; Tonar, Z; Fuchs-Baumgartinger, A; Walter, I; Skalicky, M; Witter, K; Thalhammer, JG; Pagitz, M; Kleiter, M

Title: Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs.

Source: Res Vet Sci. 2012; 92(3):444-450



Authors Vetmeduni Vienna:

Fuchs-Baumgartinger Andrea
Kleiter Miriam
Pagitz Maximilian
Skalicky Monika
Thalhammer Johann
Walter Ingrid
Witter Kirsti
Wolfesberger Birgitt

Vetmed Research Units
University Clinic for Small Animals, Clinical Unit of Internal Medicine Small Animals
Institute of Pathology
Institute of Topographical Anatomy
Institute of Physiology, Pathohysiology and Biophysics, Unit of Physiology, Pathophysiology, and Experimental Endocrinology


Abstract:
Angiogenesis, which is essential for malignancies to progress, depends on various signalling proteins including vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors 1 and 2 (VEGFR-1 and VEGFR-2). Microvessel density (MVD) is frequently used to evaluate angiogenesis. This study assessed the relationship between expression of VEGF, VEGFR-1 and VEGFR-2, MVD and the survival time in dogs with lymphoma. VEGF, VEGFR-1 and VEGFR-2 expression was evaluated immunohistochemically and microvessel profiles were counted in 34 lymphoma samples. Seventy-nine percent of the samples showed high VEGF expression and 62% were highly positive for VEGFR-1; VEGFR-2 immunoreactivity was mostly negative. Dogs treated with chemotherapy had a median survival time of 266days, but no significant relationships were found between overall survival time, MVD and expression of VEGF, VEGFR-1 or VEGFR-2. In this study, VEGF its receptors and the MVD were no prognostic factors in dogs with lymphoma.

Keywords Pubmed: Animals
Antineoplastic Agents/therapeutic use*
Biological Markers
Dog Diseases/drug therapy*
Dog Diseases/metabolism
Dogs
Female
Gene Expression Regulation, Neoplastic
Lymphoma/drug therapy
Lymphoma/metabolism
Lymphoma/veterinary*
Male
Neovascularization, Pathologic/metabolism
Neovascularization, Pathologic/veterinary*
Receptors, Vascular Endothelial Growth Factor/genetics
Receptors, Vascular Endothelial Growth Factor/metabolism
Vascular Endothelial Growth Factor A/genetics
Vascular Endothelial Growth Factor A/metabolism


© University of Veterinary Medicine ViennaHelp and DownloadsAccessibility statement